|
|
|
|
| LEADER |
02277nam a2200385 u 4500 |
| 001 |
EB001872393 |
| 003 |
EBX01000000000000001035764 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190824 r ||| eng |
| 100 |
1 |
|
|a Chao, Yi-Sheng
|
| 245 |
0 |
0 |
|a Biologics dose escalation for the treatment of inflammatory bowel disease
|h Elektronische Ressource
|b a review of clinical effectiveness, cost-effectiveness, and guidelines
|c Yi-Sheng Chao, Sarah Visintini
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa
|b CADTH
|c 2018, August 28, 2018
|
| 300 |
|
|
|a 1 PDF file (30 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Gastrointestinal Agents / economics
|
| 653 |
|
|
|a Inflammatory Bowel Diseases / drug therapy
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Antibodies, Monoclonal / therapeutic use
|
| 653 |
|
|
|a Gastrointestinal Agents / therapeutic use
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Biological Products / therapeutic use
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Biological Products / economics
|
| 653 |
|
|
|a Antibodies, Monoclonal / economics
|
| 700 |
1 |
|
|a Visintini, Sarah
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK537799
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Up to one-third of inflammatory bowel disease (IBD) patients can experience that biologics become less effective and fail to maintain disease remission. In these cases, dose intensification or more frequent dosing have been considered and tried. However, the safety profile of intensified dosing and the effects on paradoxical reactions remain a subject of research. There is a need to review the effectiveness and risks of the biologics that are infused more frequently or at higher doses. To answer this question, we aim to review the literature and compare the clinical utilities and cost-effectiveness of higher or more frequent than standard dosing of biologics with standard dosing for the treatment of IBD.
|